PVI
ARRY

Pura Vida Investments’s Array Biopharma Inc ARRY Stock Holding History

Pura Vida Investments’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$816K – 125
2018
Q1 		$816K Buy
+50,000
New +$801K 0.48% 50

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pura Vida Investments's ARRY Position: Q3 2017 in Review

Pura Vida Investments sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 265,589 shares — an estimated $2.22M sold.

Pura Vida Investments first reported a position in ARRY in Q3 2016 and held it in 4 quarters. The position peaked at $2.22M in Q2 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

  • Pura Vida Investments reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
  • Pura Vida Investments sold 265,589 Array Biopharma Inc shares in Q3 2017, an estimated $2.22M.
  • Pura Vida Investments first reported a position in Array Biopharma Inc in Q3 2016 and held it in 4 quarters.
  • Pura Vida Investments's Array Biopharma Inc position peaked at $2.22M in Q2 2017.
  • 184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.